Aptorum Group Limited (NASDAQ:APM) Sees Large Increase in Short Interest

Aptorum Group Limited (NASDAQ:APM) saw a significant increase in short interest in the month of August. As of August 31st, there was short interest totalling 6,000 shares, an increase of 33.3% from the August 15th total of 4,500 shares. Based on an average daily trading volume, of 11,300 shares, the short-interest ratio is presently 0.5 days. Approximately 0.3% of the shares of the company are sold short.

Aptorum Group Trading Down 4.2 %

Shares of Aptorum Group stock traded down $0.12 during trading on Monday, reaching $2.76. The company’s stock had a trading volume of 35,743 shares, compared to its average volume of 871,749. The company has a 50-day moving average price of $3.26 and a two-hundred day moving average price of $4.89. Aptorum Group has a fifty-two week low of $1.35 and a fifty-two week high of $17.49. The company has a debt-to-equity ratio of 0.20, a quick ratio of 1.18 and a current ratio of 1.18.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aptorum Group stock. Murchinson Ltd. purchased a new stake in Aptorum Group Limited (NASDAQ:APM) during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 14,000 shares of the company’s stock, valued at approximately $133,000. Murchinson Ltd. owned 0.27% of Aptorum Group as of its most recent SEC filing. 3.80% of the stock is owned by institutional investors.

About Aptorum Group

Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A.